Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rifaximin Clear all
Terminated Not applicable Interventional

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

NCT01951209
View directory record Official record
Conditions
Liver Cirrhosis, Chronic Hepatitis C
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
David E. Kaplan, MD MSc
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 19, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Monitoring of Stool Characteristics

NCT05604274
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
App to monitor stool consistency and symptoms
Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 19, 2026, 5:28 AM EDT
Recruiting Phase 4 Interventional

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

NCT06312683
View directory record Official record
Conditions
Pouchitis
Interventions
Rifaximin 550 MG Oral Tablet [XIFAXAN]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

NCT00577772
View directory record Official record
Conditions
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions
Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
Drug · Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing

NCT03219528
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin 550 MG, Low FODMAP Diet
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Rifaximin Therapy in Chronic Kidney Disease

NCT02342639
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Jason Stubbs, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 5:28 AM EDT
Terminated Not applicable Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.

NCT01846806
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 19, 2026, 5:28 AM EDT
Not listed Phase 2 Interventional

Rifaximin to Modify the Disease Course in Sickle Cell Disease

NCT03719729
View directory record Official record
Conditions
Sickle Cell Disease, Antibiotics
Interventions
Rifaximin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 19, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

NCT04249622
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Best Practice, Questionnaire Administration, Rifaximin
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Rifaximin With NAC in IBS-D

NCT04557215
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, N-acetylcysteine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 19, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional Results available

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

NCT00364689
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

NCT05150587
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
38
States / cities
Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 19, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

Autologous Transplant Targeted Against Crohn's

NCT04154735
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fludarabine, Cyclophosphamide, Mesna, Alemtuzumab, G-CSF, Rifaximin, Tacrolimus
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rifaximin for Chronic Immune Activation in People With HIV

NCT01866826
View directory record Official record
Conditions
HIV
Interventions
Rifaximin, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
View directory record Official record
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Induction of Clinical Response Using Rifaximin in Crohn's Disease

NCT00603616
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo Comparator, Rifaximin
Drug
Lead sponsor
Scott Lee
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?

NCT00619970
View directory record Official record
Conditions
Chronic Abdominal Pain, Small Intestinal Bacterial Overgrowth
Interventions
Lactulose Breath Test, xifaxan, placebo
Procedure · Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 18 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Xifaxan to Treat Patients With PSC

NCT01695174
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Xifaxan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 19, 2026, 5:28 AM EDT
Recruiting Phase 1 Interventional

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

NCT06298409
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
CapScan collection capsule
Device
Lead sponsor
Envivo Bio Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 4 Interventional

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

NCT03729271
View directory record Official record
Conditions
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, Glucose and lactulose hydrogen breath testing
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 19, 2026, 5:28 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex

NCT00956150
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Lactulose Breath Test, Rifaximin, Placebo
Procedure · Drug
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 19, 2026, 5:28 AM EDT
Withdrawn Phase 3 Interventional

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

NCT02086825
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 19, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

NCT00686920
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Aurora, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 19, 2026, 5:28 AM EDT